Smith C J, Phillips A N, Dauer B, Johnson M A, Lampe F C, Youle M S, Tyrer M, Staszewski S
Research Department of Infection and Population Health, Royal Free and University College Medical School, London, UK.
HIV Med. 2009 Jan;10(1):19-27. doi: 10.1111/j.1468-1293.2008.00650.x. Epub 2008 Nov 10.
More and more highly treatment-experienced patients are achieving viral suppression. However, the durability of suppression remains unclear.
Patients from Royal Free Hospital (London, UK) and JW Goethe University Hospital (Frankfurt, Germany) who had failed > or = 1 antiretroviral (ARV) regimen in all three main drug classes and > or = 3 previous ARV regimens and subsequently achieved viral load < 50 HIV-1 RNA copies/mL were included. They were followed until stopping pre-combination antiretroviral therapy, end of follow-up or viral rebound (two viral loads >400 copies/mL).
Two hundred and forty-seven patients contributed 723 person-years and 114 viral rebounds [rate=15.8 per 100 person-years; 95% confidence interval (CI) 12.9-18.7]. More recent calendar years of viral suppression [relative risk (RR)=0.90 per year later; 95% CI 0.81-1.00; P=0.05] and greater number of ARVs in the regimen not previously failed (RR=0.78 per 1 ARV more; 95% CI 0.65-0.95; P=0.01) were associated with lower viral rebound rates. At 0-1, 1-2, 2-3 and > 3 years after achieving suppression, the rebound rates were 30.9, 9.2, 4.3 and 3.5 per 100 person-years, respectively. Compared to 0-1 years, the adjusted RRs (95% CIs) after 1-2, 2-3 and > 3 years were 0.33 (0.18-0.58), 0.21 (0.09-0.48) and 0.14 (0.06-0.33), respectively (P<0.0001).
Although rebound rates are high, especially in the first year after viral suppression, this risk reduces substantially if highly treatment-experienced patients can maintain viral suppression.
越来越多接受过高度治疗的患者实现了病毒抑制。然而,抑制的持久性仍不明确。
纳入来自英国伦敦皇家自由医院和德国法兰克福歌德大学医院的患者,这些患者在所有三种主要药物类别中至少有1种抗逆转录病毒(ARV)方案治疗失败,且之前至少接受过3种ARV方案治疗,随后病毒载量<50 HIV-1 RNA拷贝/mL。对他们进行随访,直至停止联合抗逆转录病毒治疗、随访结束或病毒反弹(两次病毒载量>400拷贝/mL)。
247名患者贡献了723人年,发生114次病毒反弹[发生率=每100人年15.8次;95%置信区间(CI)12.9 - 18.7]。较近期的病毒抑制历年[相对风险(RR)=每年0.90;95% CI 0.81 - 1.00;P = 0.05]以及方案中之前未失败的ARV数量较多(每增加1种ARV,RR = 0.78;95% CI 0.65 - 0.95;P = 0.01)与较低的病毒反弹率相关。在实现抑制后的0 - 1年、1 - 2年、2 - 3年和>3年,反弹率分别为每100人年30.9次、9.2次、4.3次和3.5次。与0 - 1年相比,1 - 2年、2 - 3年和>3年后的调整后RR(95% CI)分别为0.33(0.18 - 0.58)、0.21(0.09 - 0.48)和0.14(0.06 - 0.33)(P<0.0001)。
尽管反弹率很高,尤其是在病毒抑制后的第一年,但如果接受过高度治疗的患者能够维持病毒抑制,这种风险会大幅降低。